Teva Pharmaceutical Industries Q2 Earnings Call Highlights

• MarketBeat Week successful Review – 02/03 - 02/07

Teva Pharmaceutical Industries (NYSE:TEVA) reported second-quarter 2026 gross of astir $4.1 billion, down 1% from a twelvemonth earlier successful U.S. dollars, arsenic little income from generic Revlimid were mostly offset by maturation successful its innovative medicines portfolio.

Chief Executive Officer Richard Francis said Teva's maturation strategy is progressively being driven by AUSTEDO, AJOVY and UZEDY, whose combined gross roseate 43% twelvemonth implicit twelvemonth during the quarter. The institution raised its full-year gross outlook for each 3 products and accrued the midpoint of its wide 2026 gross guidance by $75 million.

Innovative portfolio drives guidance increases

→ This Tiny AI Supplier Could Be More Important Than the Chipmakers

• Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now

AUSTEDO, Teva's attraction for tardive dyskinesia and Huntington's illness chorea, generated $676 cardinal successful U.S. gross during the quarter, up 33% twelvemonth implicit year. Global gross accrued 40%, supported by a 14% summation successful full prescriptions and 21% maturation successful milligrams dispensed, Francis said. AUSTEDO XR accounted for much than 60% of caller AUSTEDO diligent starts.

Teva raised AUSTEDO's 2026 gross guidance to a scope of $2.45 cardinal to $2.6 billion, an summation of $50 cardinal astatine the midpoint. Francis said the midpoint of the revised scope reaches the company's antecedently stated 2027 people of $2.5 cardinal and reiterated Teva's anticipation for much than $3 cardinal successful highest sales.

→ Refiner Stocks Are Near Record Highs—Can Iran-Driven Margins Keep Them There?

• 2 Generic Drug Stocks Ready to Surge successful 2025

UZEDY, a long-acting injectable attraction for schizophrenia, posted quarterly gross of $77 million, up 43% from a twelvemonth earlier. Total prescriptions and monthly bid trends accrued 63%, according to Francis. Teva raised its full-year UZEDY forecast by $15 cardinal astatine the midpoint to a scope of $270 cardinal to $290 million.

AJOVY, Teva's migraine treatment, generated planetary gross of $244 million, an summation of 56% twelvemonth implicit year. U.S. gross climbed 83%, aided by improved contracting, favorable gross-to-net trends and market-share gains, Francis said. The institution lifted AJOVY's full-year outlook by $90 cardinal astatine the midpoint to $850 cardinal to $870 cardinal and said it sees a way to $1 cardinal successful highest sales.

→ Innovative ETF Strategies That Are Paying Off This Summer

Teva is preparing for a imaginable fourth-quarter FDA enactment and U.S. motorboat of its long-acting injectable olanzapine product. The institution said it expects nary gross publication from the merchandise successful the 4th fourth due to the fact that archetypal usage would mostly dwell of samples oregon vouchers portion payer sum is established.